Vertical: CNMBase Year: 2025
Market Size (2025)
$212.26M
Projected (2032)
$290.78M
CAGR (2022–2032)
4.6%
Key Players
9+
Market Overview
The Global Coccidiostats Market was valued at USD 212.26 Million in 2025 and is projected to reach USD 290.78 Million by 2032, registering a CAGR of 4.60% over 2026–2032. In absolute terms, the market is expected to add USD 78.52 Million between 2025 and 2032. Historically, the market expanded from USD 185.42 Million in 2022 to USD 202.91 Million in 2024, supported by steady growth in commercial broiler production, the continued reliance of integrated poultry producers on in-feed anticoccidial programmes, and the progressive formalisation of poultry production in Asia Pacific, Latin America and the Middle East & Africa.
Coccidiostats are veterinary active substances, administered mainly through compound feed and premixes, that prevent or control coccidiosis, an intestinal disease caused by protozoan parasites of the genus Eimeria. Coccidiosis remains one of the most economically significant diseases of intensively reared poultry; a widely cited 2020 study by Blake et al. estimated its global cost to the chicken industry at approximately GBP 10.4 billion a year at 2016 prices, the large majority of which is attributed to sub-clinical production losses rather than mortality. Because prevention is far less costly than treatment, anticoccidial use is embedded in the standard feeding programmes of broiler producers worldwide.
Key Findings
Product type: Ionophores were the largest product type in 2025 at USD 127.36 Million (60.0% share), while Chemical Coccidiostats are the fastest-growing product type with a CAGR of 5.49% over 2026–2032.
Livestock: Broilers accounted for 75.0% of market value in 2025 (USD 159.19 Million), making it the largest livestock segment; Layers & Breeders is the fastest-growing segment at a CAGR of 5.61%.
Physical form: Premix was the dominant physical form with USD 169.81 Million (80.0% share) in 2025 and is also the faster-growing form, at a CAGR of 4.86%.
Region: Asia Pacific led the market in 2025 with USD 89.15 Million (42.0% share). Middle East & Africa is the fastest-growing region, with a CAGR of 5.47%, followed by Asia Pacific (5.28%) and Latin America (5.11%).
Country: China was the largest country market in 2025 at USD 35.66 Million, equal to 16.8% of the global market. India is the fastest-growing country, with a CAGR of 7.45% over 2026–2032.
Segmentation Summary
By product type, Ionophores held 60.0% of the market in 2025. Polyether ionophores such as monensin, salinomycin, narasin, lasalocid, maduramicin and semduramicin are cost-effective, have a broad spectrum of activity against Eimeria species, and allow a degree of natural immunity to develop, which explains their long-standing role in broiler programmes. Chemical Coccidiostats, valued at USD 84.90 Million in 2025, are forecast to grow at 5.49% and to reach USD 123.44 Million by 2032, as producers rely more on synthetic compounds such as nicarbazin, diclazuril, decoquinate and robenidine in shuttle and rotation programmes, and in production systems that restrict ionophore use.
By livestock, Broilers (USD 159.19 Million in 2025) dominate demand because coccidiostats are routinely included in starter and grower feeds for the full grow-out period. Layers & Breeders (USD 21.23 Million) is growing fastest, reflecting the expansion of commercial egg production and the need to protect pullets during rearing. Cattle & Others (USD 31.84 Million) covers cattle, sheep, goats, swine, rabbits and other species, and grows at a slower 2.75%. By physical form, Premix accounted for 80.0% of 2025 value, while Others, which includes water-soluble powders, oral solutions and suspensions, accounted for 20.0%.
Competitive Landscape Summary
The market is moderately consolidated. Elanco Animal Health, Phibro Animal Health Corporation and Huvepharma own the broadest anticoccidial portfolios, covering most of the ionophore and chemical active substances authorised for poultry. The structure of the market changed in October 2024, when Phibro completed its acquisition of Zoetis' medicated feed additive portfolio, which included anticoccidial brands such as Avatec (lasalocid), Cygro (maduramicin), Deccox (decoquinate), Robenz/Cycostat (robenidine) and Zoamix (zoalene). Zoetis thereby exited in-feed anticoccidials. Merck Animal Health and Ceva Santé Animale compete in coccidiosis control mainly through live vaccines, and both also sell anticoccidial drugs for ruminants and swine. Regional and generic suppliers such as Virbac, Krka, Dopharma and Bimeda, together with Chinese fermentation-based producers of ionophore active ingredients, compete mainly on price in specific geographies.
Challenges and Opportunities
The main challenges are the development of resistance in field Eimeria populations, which shortens the effective life of individual active substances, and retailer- and consumer-driven antibiotic-free production claims. In the United States, ionophores are classified as antimicrobials for labelling purposes, so they cannot be used in flocks marketed as raised without antibiotics. Regulatory re-authorisation of coccidiostats in the European Union, where authorisations are holder-specific and must be renewed every ten years, adds cost and uncertainty. On the opportunity side, rising poultry meat output in Asia Pacific, Latin America and the Middle East & Africa; the adoption of structured rotation and shuttle programmes that use both ionophores and chemicals; and the integration of anticoccidials with vaccination and gut-health programmes all support continued growth. Several producers have also moved from 'No Antibiotics Ever' claims to claims that permit ionophores, which supports ionophore demand.
Future Outlook
Over 2026–2032, the market is expected to grow at a moderate and stable pace, rising from USD 222.04 Million in 2026 to USD 290.78 Million in 2032. Growth will be concentrated in emerging poultry economies: Asia Pacific is projected to reach USD 127.83 Million by 2032 and to increase its global share from 42.0% in 2025 to 44.0% in 2032. India, with a CAGR of 7.45%, will be the fastest-growing country market. China will remain the largest, rising from USD 35.66 Million in 2025 to USD 46.93 Million in 2032. Chemical Coccidiostats are expected to gain share, from 40.0% in 2025 to 42.5% in 2032, as producers diversify anticoccidial programmes to manage resistance.
The Coccidiostats Market market is projected to grow at a CAGR of 4.6% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Coccidiostats (also referred to as anticoccidials) are substances intended to kill or inhibit protozoan parasites of the subclass Coccidia, principally Eimeria species in poultry and ruminants and Cystoisospora species in pigs. In poultry, seven Eimeria species infect the chicken, including E. acervulina, E. maxima and E. tenella. They invade the intestinal epithelium, causing lesions, impaired nutrient absorption, poorer feed conversion, reduced weight gain and, in clinical cases, mortality. Coccidiostats are used mainly for prevention: they are included continuously in feed during the high-risk rearing period, so that parasite multiplication stays below the level that causes economic loss.
Coccidiostats fall into two chemical groups. Ionophores are polyether compounds produced by fermentation of Streptomyces and related microorganisms. Monovalent ionophores include monensin, salinomycin and narasin; monovalent glycosidic ionophores include maduramicin and semduramicin; and lasalocid is a divalent ionophore. They act by disrupting ion transport across the parasite cell membrane. Chemical (synthetic) coccidiostats are produced by chemical synthesis and have specific modes of action. They include nicarbazin, diclazuril, decoquinate, robenidine, halofuginone, clopidol, amprolium, toltrazuril, zoalene and the sulfonamides.
Included in the scope of this study:
Ionophore and chemical coccidiostats authorised as feed additives or veterinary medicinal products for the prevention and control of coccidiosis
Products supplied as premixes for incorporation into compound feed, and in other forms such as water-soluble powders, oral solutions and oral suspensions
Use in broilers, layers and breeders, cattle and other species (including sheep, goats, swine, rabbits and turkeys or game birds where grouped under 'Others')
Single-active and combination products, such as narasin + nicarbazin or monensin + nicarbazin
Excluded from the scope of this study:
Live attenuated and non-attenuated coccidiosis vaccines
Phytogenic, probiotic, prebiotic, organic acid and other gut-health feed additives that are not authorised as coccidiostats
Products authorised only as histomonostats, and antimicrobials used only as growth promoters or for bacterial disease
Human medicinal products and diagnostic services
Scope of the Study
This study quantifies the global coccidiostats market by product type, livestock, physical form and region, with country-level analysis within each region. Market values are presented in USD Million for the historic years 2022–2024, the base year 2025 and the forecast years 2026–2032. Compound annual growth rates refer to the period 2026–2032.
Research Objectives
To estimate the size of the global coccidiostats market from 2022 to 2025 and forecast it to 2032 in USD Million
To analyse the market by product type (Ionophores and Chemical Coccidiostats) and assess how demand is shifting between the two groups
To quantify demand by livestock category (Broilers, Layers & Breeders, Cattle & Others) and relate it to poultry and livestock production trends
To evaluate the market by physical form (Premix and Others) in the context of feed-mill and on-farm administration practices
To assess the market across five regions and their key countries, and identify the fastest-growing geographies
To examine the drivers, restraints, opportunities, trends and challenges influencing anticoccidial use, including resistance and antibiotic-free production
To review the regulatory frameworks that govern authorisation, use and residue limits of coccidiostats in major regions
To profile the competitive environment, including the positioning of leading suppliers and key developments since 2022
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study followed a structured, multi-stage process. It began with a definition of the market scope and segmentation, followed by extensive secondary research. Primary research was then used to validate and refine the findings. Market size was estimated through top-down and bottom-up approaches, and the results were triangulated to reconcile differences. The final stage was a forecast built on quantified drivers and restraints. Each stage included quality checks for internal consistency across segments, regions and years.
Stage 1 – Scoping: definition of coccidiostats, inclusion and exclusion criteria, segmentation framework and geographic coverage
Stage 2 – Secondary research: collection of production, trade, regulatory, company and product data
Stage 3 – Primary research: discussions with industry participants across the value chain to validate assumptions
Stage 4 – Market estimation: top-down and bottom-up sizing, with triangulation
Stage 5 – Forecasting and validation: projection to 2032, followed by internal review and consistency checks
Secondary Research
Secondary research covered the following source types relevant to the animal health and feed additive industry:
Government and regulatory bodies: the US Food and Drug Administration Center for Veterinary Medicine (approvals, antimicrobial sales reports), USDA Foreign Agricultural Service and FSIS, the European Commission and the EU Register of Feed Additives, EFSA FEEDAP opinions, China's Ministry of Agriculture and Rural Affairs, India's Department of Animal Husbandry and Dairying, and Brazil's Ministry of Agriculture and Livestock
International organisations: FAO statistics and meat market reviews, the OECD-FAO Agricultural Outlook, Codex Alimentarius residue standards and the WOAH list of antimicrobial agents of veterinary importance
Industry associations: national and regional poultry, feed and animal health associations, such as feed manufacturers' federations and animal health industry bodies
Company sources: annual reports, SEC filings, investor presentations, product labels and press releases of animal health companies
Trade and scientific journals: poultry and feed industry publications and peer-reviewed literature on coccidiosis epidemiology, anticoccidial resistance and the economic impact of the disease
Paid databases: trade statistics, company financial databases and feed production databases
Primary Research
Primary research was conducted to validate market estimates, segment splits and qualitative findings. Discussions were held with supply-side and demand-side participants.
Supply side: product managers, technical service veterinarians, regulatory affairs specialists and sales executives of anticoccidial manufacturers, premix producers and distributors
Demand side: nutritionists and veterinarians at integrated poultry companies, compound feed mills, layer and breeder operations and cattle feedlots, as well as independent poultry health consultants
Objectives: to validate market size and growth assumptions, understand product preferences and programme design (shuttle and rotation), assess pricing trends and the impact of antibiotic-free production, and identify emerging competitive developments
Market Size Estimation
The bottom-up approach estimated demand from livestock populations and production volumes, mainly broiler placements and slaughter numbers, layer and breeder flock sizes, and cattle and small ruminant populations. These were multiplied by the share of animals receiving coccidiostats, typical inclusion rates and treatment durations, and average prices by product type and form. Country estimates were aggregated to regional and global totals.
The top-down approach started from the revenues of leading anticoccidial suppliers and the overall size of the medicated feed additive and animal health markets. These were allocated to product types, livestock and regions using company disclosures, regulatory data and expert inputs. The two sets of results were triangulated, and any differences were investigated and reconciled to arrive at the final market estimates.
Forecasting Methodology
Forecasts for 2026–2032 were developed by projecting the base-year market using the following factors:
Projected poultry meat and egg production by country, and growth in commercial (integrated) production relative to backyard systems
Changes in the share of flocks under anticoccidial programmes, including the impact of antibiotic-free production and vaccination
Regulatory developments affecting authorisation, use and residue limits of coccidiostats
Shifts in product mix between ionophores and chemical coccidiostats driven by resistance management practices
Price trends, including the effect of generic competition and raw material costs
Macroeconomic indicators such as population growth, income growth and protein consumption
Each factor was assessed for its direction and strength of impact over the short, medium and long term, and the results were validated through primary research.
Base Year, Forecast Period and Currency
Assumptions and Limitations
Market values are estimated at the manufacturer or first-seller level and exclude value added by feed mills when coccidiostats are incorporated into compound feed
Exchange rates are assumed to remain broadly stable at base-year levels over the forecast period
No major regulatory ban on ionophores or widely used chemical coccidiostats is assumed in the major producing regions during the forecast period
Livestock disease outbreaks, such as highly pathogenic avian influenza, are assumed to cause temporary rather than structural reductions in flock sizes
The rate at which vaccination and antibiotic-free programmes replace in-feed coccidiostats is assumed to continue at a gradual pace
Data on privately held companies and on some emerging markets is limited, and estimates for these areas rely to a greater degree on primary research and modelling
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The global coccidiostats market is moderately consolidated. A small number of multinational animal health companies own most of the branded ionophore and chemical anticoccidial products authorised in major markets, and the fermentation capacity required to produce ionophores is concentrated among a few manufacturers. Alongside these leaders, regional and generic suppliers compete on price, especially in Asia Pacific, Latin America and the Middle East & Africa. Chinese fermentation-based producers also supply active ingredients and finished products in these markets.
Competition is based on the breadth of the anticoccidial portfolio, the ability to support shuttle and rotation programmes, regulatory authorisations in key markets, manufacturing scale and cost, and technical service to integrators and feed mills. Ownership of the category consolidated further in 2024, when Phibro acquired Zoetis' medicated feed additive portfolio and Zoetis exited in-feed anticoccidials. Companies focused on coccidiosis vaccines, such as Merck Animal Health and Ceva, compete for the same coccidiosis-control budgets, particularly in breeders, layers and antibiotic-free broilers.
Key Player Positioning
Market Leaders
Elanco Animal Health (U.S.): Elanco has one of the strongest ionophore franchises, including Monteban (narasin), Maxiban (narasin + nicarbazin), Coban (monensin) and Rumensin (monensin) for cattle, together with the chemical coccidiostats Clinacox (diclazuril) and ZoaShield (zoalene) and Baycox (toltrazuril). The company reported revenue of USD 4,715 million for fiscal year 2025. It positions its poultry portfolio for both conventional and antibiotic-free producers.
Phibro Animal Health Corporation (U.S.): Phibro has the broadest in-feed anticoccidial range following its acquisition of the Zoetis medicated feed additive portfolio in October 2024. Its products include Coxistac (salinomycin), Aviax (semduramicin), Nicarb (nicarbazin), Amprolium, Avatec and Bovatec (lasalocid), Cygro (maduramicin), Deccox (decoquinate), Robenz/Cycostat (robenidine) and Zoamix (zoalene). Phibro reported net sales of USD 1,518.1 million for the fiscal year ended June 2026.
Huvepharma (Bulgaria): Huvepharma is a privately held, fermentation-based manufacturer with a complete coccidiosis-control portfolio, including Sacox (salinomycin), Coxidin (monensin), Yumamycin (maduramicin), Monimax (monensin + nicarbazin), Coxiril (diclazuril), Stenorol (halofuginone) and Coyden (clopidol), as well as coccidiosis vaccines. The company does not publish consolidated audited revenue.
Challengers
Merck Animal Health (MSD Animal Health) (U.S.): Merck competes in coccidiosis control mainly through its Coccivac and Paracox live vaccines for poultry, and through Vecoxan (diclazuril) for calves and lambs. Merck & Co. reported Animal Health sales of USD 6,354 million for fiscal year 2025.
Ceva Santé Animale (France): Ceva focuses on vaccination-led coccidiosis control through its Immucox range, and sells Cevazuril (toltrazuril) for piglets and calves. The company reported turnover of EUR 1.92 billion for fiscal year 2025.
Niche and Regional Players
Virbac (France): Virbac supplies regional anticoccidial products such as Virbacox (salinomycin) in South Africa and amprolium soluble powder in India. It reported revenue of EUR 1,465 million for fiscal year 2025.
Krka d.d. (Slovenia): Krka produces its own toltrazuril active ingredient and markets Toltarox (toltrazuril) for piglets and Kokcisan (salinomycin) for broilers in Europe. The group reported revenue of EUR 2,041 million for fiscal year 2025, of which animal health accounted for EUR 114.7 million.
Dopharma (Netherlands): Dopharma is a family-owned veterinary pharmaceutical company supplying generic coccidiosis products such as Dozuril (toltrazuril) and sulfonamides for poultry. It does not publish revenue.
Bimeda (Ireland): Bimeda is a generic animal health manufacturer offering AmproMed (amprolium) products for poultry and calves in the U.S. It does not publish revenue.
Competitor Dashboard
The dashboard below rates each profiled company on four parameters relevant to its competitive position in the coccidiostats market.
Threat of New Entrants – Low
Registration of coccidiostats requires extensive safety, efficacy and residue data, and EU authorisations are holder-specific
Fermentation-based manufacture of ionophores is capital-intensive and requires proprietary strains and process know-how
Established suppliers have long-standing relationships with integrators and feed mills, supported by technical service teams
Bargaining Power of Suppliers – Medium
Fermentation substrates and chemical intermediates are widely available, but energy and logistics costs affect prices
Some intermediates and generic active ingredients are concentrated in China, creating supply risk
Leading players are vertically integrated into active ingredient manufacture, which limits supplier leverage
Bargaining Power of Buyers – High
Large integrators and feed mills buy in volume and run competitive tenders for anticoccidial programmes
Buyers can switch between ionophores, chemicals and vaccines as part of rotation programmes
Generic versions of many active substances are available, which increases price pressure
Threat of Substitutes – Medium
Live coccidiosis vaccines are an established alternative, particularly in breeders, layers and antibiotic-free broilers
Phytogenic and other gut-health additives are marketed as supportive tools but generally lack equivalent efficacy as stand-alone solutions
For most conventional broiler production, in-feed coccidiostats remain the most cost-effective option
Intensity of Competitive Rivalry – High
A small number of multinational suppliers compete across overlapping active substances and brands
Generic products compete strongly on price in Asia Pacific, Latin America and the Middle East & Africa
Competition increasingly centres on programme design, technical service and broad portfolios rather than single products
Threat of New Entrants: Low; High regulatory and manufacturing barriers.
Bargaining Power of Suppliers: Medium; Available inputs, but concentration in some intermediates.
Bargaining Power of Buyers: High; Large, consolidated buyers and generic availability.
Threat of Substitutes: Medium; Vaccines and gut-health additives in specific segments.
Competitive Rivalry: High; Overlapping portfolios and generic price competition.
Market estimates by geography (2032)
InsightAsia Pacific leads with $127.83M by 2032, while Middle East & Africa is projected to grow fastest at a 5.4% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $34.38M | $40.64M | $47.25M | 3.2% | 16% |
| Europe | $29.48M | $34.00M | $39.95M | 3.1% | 14% |
| Asia Pacific | $75.93M | $98.85M | $127.83M | 5.3% | 44% |
| Latin America | $32.93M | $42.22M | $54.17M | 5.1% | 19% |
| Middle East & Africa | $12.70M | $16.54M | $21.58M | 5.4% | 7% |
| Total | $185.42M | $232.26M | $290.78M | 4.6% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$290.78M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Ionophores | $167.35M | 4.0% | 58% |
| Chemical Coccidiostats | $123.44M | 5.5% | 42% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Coccidiostats Market covering market dynamics, competitive landscape, and strategic outlook.
The Coccidiostats Market market is projected to reach $290.78M by 2032, growing at 4.6% CAGR. The Ionophores segment holds the largest share.
The coccidiostats market is shaped by the scale and structure of global poultry production, the economic burden of coccidiosis, and the regulatory and commercial response to antimicrobial resistance. Demand is driven mainly by the number of broilers reared under commercial conditions, which in turn reflects the growing consumption of poultry meat as an affordable protein. Growth is moderated by resistance development, antibiotic-free production claims and the gradual adoption of vaccination. This chapter assesses these forces.
Growth in Global Poultry Meat Production
Poultry is the most widely consumed and fastest-growing meat category worldwide. It has a short production cycle and efficient feed conversion, and faces few religious or cultural restrictions. According to the US Department of Agriculture Foreign Agricultural Service, global chicken meat production reached approximately 108.0 million tonnes (ready-to-cook basis) in 2025 and was forecast to rise by about 3% to roughly 110.7 million tonnes in 2026. Production growth is led by the United States, China and Brazil. The OECD-FAO Agricultural Outlook 2026–2035 projects poultry to account for the largest absolute increase in meat consumption over the next decade. Almost every commercial broiler flock is reared under some form of coccidiosis control, and in most markets in-feed coccidiostats remain the default. Growth in broiler placements therefore translates directly into higher coccidiostat demand. The effect is strongest in Asia Pacific, Latin America and the Middle East & Africa, where production is expanding and moving from backyard to commercial systems.
High Economic Burden of Coccidiosis
Coccidiosis is endemic wherever poultry are reared on litter at high stocking densities, because the oocysts are environmentally resistant and are present on virtually all commercial farms. A 2020 study by Blake and co-authors, published in Veterinary Research, re-calculated the global cost of coccidiosis in chickens at approximately GBP 10.4 billion a year at 2016 prices, equivalent to about GBP 0.16 per chicken produced. More than 80% of this cost in the countries studied came from sub-clinical losses such as reduced weight gain and poorer feed conversion, rather than from treatment or mortality. Coccidial damage to the intestine also predisposes birds to necrotic enteritis caused by Clostridium perfringens. Because the cost of in-feed prevention is small relative to these losses, producers treat anticoccidial programmes as essential. This underpins stable, non-discretionary demand even when producer margins are under pressure. Producers also track the performance of anticoccidial programmes closely through lesion scoring, feed conversion and weight-gain data, which reinforces the commercial case for maintaining effective programmes in every flock.
Industrialisation and Integration of Poultry Production
In emerging markets, poultry production is shifting from backyard and small independent farms to vertically integrated companies that control breeding, feed milling, rearing and processing. Integrators formulate feed centrally, follow structured health programmes under veterinary supervision, and buy anticoccidials in premix form for continuous inclusion in feed. This model is well established in the United States, Brazil and Western Europe, and is expanding in India, Southeast Asia, the Gulf states and parts of Africa. In China, the consolidation of small farms into larger operations in recent years has had a similar effect. Each step of integration raises the proportion of birds receiving coccidiostats at recommended doses, and supports demand for premix products and for technical services from suppliers. Integrated companies also adopt the shuttle and rotation programmes used in mature markets, which increases demand for both ionophores and chemical coccidiostats. Investment by multinational suppliers in local registrations, affiliates and technical teams in Asia and Africa further supports adoption.
Continued Regulatory Acceptance of Coccidiostats
Regulators have generally distinguished coccidiostats from antimicrobial growth promoters. The European Union banned antibiotic growth promoters in 2006 but continues to authorise coccidiostats as feed additives under Regulation (EC) No 1831/2003; recent renewals include lasalocid (2023), semduramicin (2024), monensin (2026) and diclazuril (2026). The US FDA classifies ionophores as not medically important antimicrobials, so they fall outside the guidance that moved medically important feed antimicrobials to veterinary oversight. China's Ministry of Agriculture and Rural Affairs Announcement No. 194 withdrew growth-promoting feed additives from 2020, but anticoccidials were moved to veterinary drug approval numbers and remain permitted in feed. The WOAH notes that ionophores are used only in animals. This regulatory position allows coccidiostat use to continue and, in some cases, to grow as other in-feed antimicrobials are withdrawn. Because coccidiostats are also governed by residue limits and withdrawal periods, regulatory acceptance comes with clear conditions of use, which gives feed mills and integrators confidence in the products they buy.
Rapid Expansion of Poultry Production in Emerging Markets
Emerging economies offer the largest incremental opportunity. Asia Pacific is projected to add USD 38.68 Million between 2025 and 2032, and India is the fastest-growing country market at a CAGR of 7.45%. Saudi Arabia and the UAE are investing in domestic poultry capacity to improve food security, while Brazil and Argentina continue to expand export-oriented production. Suppliers with local registration, technical service teams and distribution networks in these markets are well placed to benefit.
Integrated Coccidiosis Management Programmes
Producers increasingly design coccidiosis control as a programme rather than a single product. Such programmes may combine chemical coccidiostats in starter feeds with ionophores in grower feeds (shuttle programmes), rotate active substances between flocks, or alternate vaccination and anticoccidial cycles to restore parasite sensitivity. This creates an opportunity for suppliers with broad portfolios across ionophores, chemicals, combinations and vaccines to offer complete programmes, supported by diagnostics such as lesion scoring and anticoccidial sensitivity testing.
Re-introduction of Ionophores under Revised Label Claims
Some US producers have reconsidered strict 'No Antibiotics Ever' policies because of their cost and their impact on bird health and welfare. In 2023, Tyson Foods announced that it would reintroduce ionophores in part of its chicken supply and move those products to a 'No Antibiotics Important to Human Medicine' claim. As ionophores have no use in human medicine, wider adoption of such claims would reopen a part of the market previously closed to ionophores and support demand for these products in North America.
Development of Anticoccidial Resistance
Eimeria parasites have developed resistance to virtually every anticoccidial introduced since the 1940s. Resistance tends to develop fastest to chemical compounds with a single mode of action, and more slowly to ionophores. When field populations become less sensitive to a product, its efficacy and commercial value decline, and producers must rotate to other active substances or switch to vaccination. Very few new anticoccidial molecules have been introduced in recent decades, so the industry depends on a limited set of active substances. Over time, this restricts the value that can be captured from individual products and requires investment in sensitivity testing and programme design.
Antibiotic-Free Production Claims and Vaccination
In the United States, ionophores are considered antibiotics for meat labelling purposes, so flocks raised for 'No Antibiotics Ever' (NAE) or 'raised without antibiotics' programmes cannot receive them. Growth of these programmes in the 2010s shifted coccidiosis control towards chemical coccidiostats and live vaccines. Vaccine suppliers such as Merck Animal Health, Ceva Santé Animale, Huvepharma and Phibro promote vaccination as an alternative in antibiotic-free and breeder flocks. In Europe, retailer standards and national stewardship plans add further pressure to reduce in-feed medication. These trends limit the volume growth of ionophores in mature markets.
Regulatory Re-authorisation Costs and Residue Requirements
In the European Union, coccidiostat authorisations are holder-specific and must be renewed every ten years, supported by updated safety and efficacy dossiers reviewed by the European Food Safety Authority. Maximum residue limits in food, and limits for unavoidable carry-over into non-target feed, impose withdrawal periods and strict feed-mill controls. These requirements raise compliance costs, discourage new entrants and can lead to the withdrawal of products or uses for which renewal is not economically justified.
Shift towards Chemical Coccidiostats in Shuttle Programmes
Chemical Coccidiostats are growing faster than Ionophores in every region covered by this study. Globally, the segment is forecast to grow at 5.49% against 3.98% for Ionophores. This reflects their use in antibiotic-free production, their role in starter feeds within shuttle programmes, and their value in rotation for resistance management.
Consolidation of Anticoccidial Portfolios
Ownership of anticoccidial brands has become more concentrated. Phibro's acquisition of the Zoetis medicated feed additive portfolio in October 2024 brought lasalocid, maduramicin, decoquinate, robenidine and zoalene products together with Phibro's existing salinomycin, semduramicin, nicarbazin and amprolium lines. Huvepharma has built its range through successive acquisitions and fermentation capacity investments, including the agreement announced in July 2026 to acquire Euroapi Italy and its Brindisi fermentation site.
Growing Role of Vaccination and Non-Antimicrobial Alternatives
Live coccidiosis vaccines are increasingly used in breeders, layers and antibiotic-free broilers, and suppliers are investing in vaccine capacity. For example, Ceva announced a new coccidiosis vaccine plant in Guelph, Canada in 2023 and launched Immucox 5 for laying hens in Brazil in 2025. Phytogenic and other gut-health additives are also marketed as supportive tools. These products complement rather than fully replace coccidiostats in most markets, but they limit the growth of in-feed use in some segments.
Challenge of Maintaining Product Efficacy
With a limited pipeline of new active substances, the industry's main challenge is to preserve the efficacy of existing products. This requires disciplined rotation, monitoring of field sensitivity, correct inclusion rates and the integration of vaccination. Suppliers that support customers in these areas are better placed to keep their products effective.
The coccidiostats value chain runs from raw material supply through active ingredient manufacture, premix formulation and distribution to end users at the farm level.
Raw materials and inputs: Ionophores are produced by fermentation, which requires carbohydrate and protein substrates (such as starch, glucose and soybean meal), proprietary production strains and energy. Chemical coccidiostats are produced by multi-step chemical synthesis from organic intermediates and solvents. A significant share of global active ingredient and intermediate capacity is located in China and Europe.
Active ingredient manufacturing: Manufacturers ferment or synthesise the active substance, then purify, dry and test it under good manufacturing practice. Fermentation is capital-intensive and scale-dependent, which favours established players such as Huvepharma, Elanco and Phibro, as well as large Chinese producers.
Formulation and premix production: Active substances are formulated into granular premixes on carriers, or into water-soluble powders and oral solutions. Formulation determines stability, homogeneity in feed and dust control. Products must be registered with the competent authorities in each market.
Distribution and channels: Products are sold directly to integrators and large feed mills, or through premix companies, veterinary distributors and local agents. Technical service, including programme design and sensitivity testing, is an important part of the commercial offer.
End users: Compound feed mills incorporate premixes into poultry and livestock feed. Integrated poultry companies, independent broiler and layer farms, breeder operations, cattle feedlots and small ruminant farms use the medicated feed or administer water-soluble and oral products directly.
North America
In the United States, coccidiostats for use in feed are approved by the FDA Center for Veterinary Medicine as new animal drugs, and their permitted uses in medicated feed are codified in 21 CFR Part 558.
The FDA classifies ionophores as not medically important antimicrobials. Guidance for Industry #213 (2013) and the Veterinary Feed Directive final rule (2015) moved medically important feed antimicrobials to veterinary oversight. Guidance for Industry #263 moved the remaining over-the-counter medically important antimicrobials to prescription status by June 2023. Ionophores were not within the scope of these measures.
The FDA withdrew approvals of the arsenical compounds roxarsone, carbarsone and arsanilic acid in 2013–2014, and nitarsone in 2015, removing these products from US poultry programmes.
Animal-raising claims on meat labels, including antibiotic-free claims, are overseen by USDA FSIS, which issued an updated guideline on substantiating animal-raising claims in 2024.
In Canada, veterinary drugs including coccidiostats are regulated by Health Canada's Veterinary Drugs Directorate, and medicated feeds are regulated under the Feeds Act and Regulations administered by the Canadian Food Inspection Agency.
Europe
In the European Union, coccidiostats and histomonostats are a category of feed additive authorised under Regulation (EC) No 1831/2003. Authorisations are granted to specific holders for ten years, following a scientific assessment by the EFSA FEEDAP Panel.
Recent renewals include Implementing Regulation (EU) 2023/1172 (lasalocid A sodium, Avatec 150G), Implementing Regulation (EU) 2024/2389 (semduramicin sodium, Aviax 5%) and Implementing Regulation (EU) 2026/532 (monensin sodium, Coxidin), which also added uses in turkeys.
Commission Directive 2009/8/EC and Commission Regulation (EU) No 574/2011 set maximum levels for unavoidable carry-over of coccidiostats into non-target feed. Commission Regulation (EC) No 124/2009 sets the corresponding maximum levels in food.
Regulation (EU) 2019/6 on veterinary medicinal products and Regulation (EU) 2019/4 on medicated feed apply from January 2022 and govern coccidiostats authorised as veterinary medicines, such as toltrazuril and diclazuril oral products.
In Great Britain, feed additive authorisations are managed by the Food Standards Agency under retained legislation; for example, The Feed Additives (Authorisations) (England) Regulations 2022 authorised decoquinate products. Veterinary medicines are regulated by the Veterinary Medicines Directorate.
Asia Pacific
In China, Ministry of Agriculture and Rural Affairs Announcement No. 194 (2019) withdrew growth-promoting medicated feed additives from 2020. Anticoccidials were retained, with their approval numbers converted to veterinary drug approval numbers, and may still be used in commercial feed.
In India, the Ministry of Health and Family Welfare banned colistin for food-producing animals, poultry, aquaculture and animal feed supplements in 2019 (S.O. 2607(E)), and banned chloramphenicol and nitrofurans for food-producing animals in 2025 (S.O. 1158(E)). The Prevention of Cruelty to Animals (Egg Laying Hens) Rules, 2023 prohibit antimicrobial growth promoters in laying hens. These measures do not target coccidiostats but increase scrutiny of in-feed medication.
In Japan, veterinary drugs and feed additives are regulated by the Ministry of Agriculture, Forestry and Fisheries, and residues in food are controlled under the positive list system.
Latin America
In Brazil, the Ministry of Agriculture and Livestock (MAPA) regulates feed additives under Normative Instruction No. 13 of 2004, which defines anticoccidials as a distinct additive category.
MAPA has progressively restricted antimicrobials used as performance enhancers, for example through Normative Instruction No. 1 of 2020, which banned tylosin, lincomycin and tiamulin for that purpose.
In Argentina, veterinary products and feed additives are registered and controlled by the National Agri-Food Health and Quality Service (SENASA).
Middle East & Africa and International Standards
In the Middle East & Africa, veterinary drug and feed additive registration is handled by national authorities, such as the Saudi Food and Drug Authority and South Africa's registration system for farm feeds and veterinary remedies under Act 36 of 1947.
The Codex Alimentarius Commission sets maximum residue limits for several coccidiostats, including diclazuril, monensin, narasin and nicarbazin, which serve as a reference for national standards and international trade.
The WOAH List of Antimicrobial Agents of Veterinary Importance includes the ionophores and notes that this class is used only in animals.
Aug 2022: Bimeda; Acquisition; Acquired Afrivet, a South African animal health company with operations in Zambia and Mozambique, expanding its presence in Africa.
Dec 2022: Ceva Santé Animale; Acquisition; Acquired Zoovet and Biotecnofe in Argentina, adding a biotechnology campus in Santa Fe.
Jun 2023: Zoetis; Regulatory approval; The EU renewed the authorisation of lasalocid A sodium (Avatec 150G) for chickens for fattening under Implementing Regulation (EU) 2023/1172.
Sep 2023: Ceva Santé Animale; Expansion; Announced a new manufacturing plant in Guelph, Canada, to expand global supply of coccidiosis vaccines.
Apr 2024: Phibro Animal Health / Zoetis; Acquisition agreement; Phibro agreed to acquire Zoetis' medicated feed additive portfolio and certain water-soluble products for USD 350 million, covering more than 37 product lines and six manufacturing sites.
Apr 2024: Virbac; Acquisition; Completed the acquisition of Sasaeah, a Japanese farm-animal vaccine and pharmaceutical company with plants in Japan and Vietnam.
Aug 2024: Huvepharma; Regulatory approval; Received US FDA approval for Coxidin (monensin) under an abbreviated new animal drug application.
Sep 2024: Phibro Animal Health; Regulatory approval; The EU renewed the authorisation of semduramicin sodium (Aviax 5%) for chickens for fattening under Implementing Regulation (EU) 2024/2389.
Oct 2024: Phibro Animal Health; Acquisition; Completed the acquisition of Zoetis' medicated feed additive portfolio, including anticoccidial brands and manufacturing sites in the U.S., Italy and China.
2024: Huvepharma; Expansion; Opened a new vaccine production plant in Razgrad, Bulgaria.
Mar 2025: Ceva Santé Animale; Product launch; Launched the Immucox 5 coccidiosis vaccine for laying hens in Brazil.
Mar 2026: Huvepharma; Regulatory approval; The EU renewed the authorisation of monensin sodium (Coxidin) and added uses in turkeys under Implementing Regulation (EU) 2026/532.
Apr 2026: Bimeda; Acquisition; Acquired selected non-sterile manufacturing assets at Dechra's Pomona, California site.
Jul 2026: Huvepharma; Acquisition agreement; Agreed to acquire 100% of Euroapi Italy S.r.l. and its Brindisi fermentation site, increasing its fermentation capacity by 25%.
Sep 2026: Elanco Animal Health; Regulatory approval; The EU renewed the authorisation of diclazuril (Clinacox 0.5%) for chickens for fattening and chickens reared for laying under Implementing Regulation (EU) 2026/2086.
Political: Government food security strategies in the Gulf states, India and Africa support investment in domestic poultry production. National action plans on antimicrobial resistance shape policy on in-feed medication. Trade policy and sanitary agreements affect poultry export markets such as Brazil and the United States.
Economic: Poultry is the lowest-cost animal protein in most markets, which supports demand during economic downturns. Feed grain prices and producer margins influence spending on feed additives. Currency fluctuations affect the cost of imported active ingredients in emerging markets.
Social: Rising incomes and urbanisation increase protein consumption. Consumer interest in antibiotic-free and higher-welfare products influences production claims. Awareness of antimicrobial resistance is rising among consumers and retailers.
Technological: Advances in fermentation efficiency and premix formulation reduce production costs and improve feed stability. Diagnostic tools such as sensitivity testing support programme design. Progress in vaccine technology provides alternative tools.
Environmental: Fermentation and synthesis plants are subject to environmental permits for effluent and emissions. Better coccidiosis control improves feed efficiency and lowers the environmental footprint per kilogram of meat. Climate-related heat stress and disease patterns affect flock health.
Legal: Coccidiostats require product-specific authorisation, with periodic renewal in the EU. Maximum residue limits, withdrawal periods and carry-over limits apply. Meat labelling rules determine whether ionophores are compatible with antibiotic-free claims.
Profiles of 33 companies operating in the Coccidiostats Market market, including revenue, employee count, and market positioning where available.
Showing 33 of 33 companies
Company Headquarters: Carros, Southeastern France, France Founded: 1968 Workforce: ~4825 Company Working: Virbac develops, manufactures, and markets a wide range of veterinary pharmaceutical products and has a market experience of more than fifty years and is one of the top 10 players in the global animal health market. It operates through the livestock and aquaculture business segments, and manufactures products including parasiticides, immunology, antibiotics/dermatology, specialties, equine, and specialized pet food. The company has a presence in more than 100 countries and generates more than 60% of its revenue from outside Europe. It has 11 manufacturing units in different countries and five fully equipped R&D facilities for the development of products.
4 interactive charts drawn from the Coccidiostats Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Coccidiostats Market By Physical Form
Global Coccidiostats Market By Livestock
Global Coccidiostats Market By Product Type
Global Coccidiostats Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
